Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate

Anna Migdalska-Richards, Wai Kin D Ko, Qin Li, Erwan Bezard, Anthony H V Schapira, Anna Migdalska-Richards, Wai Kin D Ko, Qin Li, Erwan Bezard, Anthony H V Schapira

Abstract

Mutations in the glucocerebrosidase 1 (GBA1) gene are related to both Parkinson disease (PD) and Gaucher disease (GD). In both cases, the condition is associated with deficiency of glucocerebrosidase (GCase), the enzyme encoded by GBA1. Ambroxol is a small molecule chaperone that has been shown in mice to cross the blood-brain barrier, increase GCase activity and reduce alpha-synuclein protein levels. In this study, we analyze the effect of ambroxol treatment on GCase activity in healthy nonhuman primates. We show that daily administration of ambroxol results in increased brain GCase activity. Our work further indicates that ambroxol should be investigated as a novel therapy for both PD and neuronopathic GD in humans.

Keywords: Parkinson disease; ambroxol; glucocerebrosidase; nonhuman primate.

© 2017 The Authors Synapse Published by Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
Glucocerebrosidase (GCase) and β‐hexosaminidase (HEXB) activity after daily treatment with different levels of ambroxol. (a–d) GCase activity did not increase with 22.5 mg ambroxol treatment in any region, but increased by about 20% in the midbrain, cortex and striatum and 5% in the cerebellum with 100 mg treatment. (e‐h) HEXB activity was increased by about 20% in the midbrain, cortex, and striatum, but not in the cerebellum, when treated with 100 mg ambroxol

References

    1. Beutler, E. (1992). Gaucher disease: New molecular approaches to diagnosis and treatment. Science, 256, 794–799.
    1. Bourdenx, M. , Nilsson, A. , Wadensten, H. , Fälth, M. , Li, Q. , Crossman, A. R. , …, Bezard, E. (2014). Abnormal structure‐specific peptide transmission and processing in a primate model of Parkinson's disease and l‐DOPA‐induced dyskinesia. Neurobiology Disease, 62, 307–312.
    1. Bultron, G. , Kacena, K. , Pearson, D. , Boxer, M. , Yang, R. , Sathe, S. , … Mistry, P. K. (2010). The risk of Parkinson's disease in type 1 Gaucher disease. Journal of Inherited Metabolic Disease, 33, 167–173.
    1. Gegg, M. E. , Burke, D. , Heales, S. J. , Cooper, J. M. , Hardy, J. , Wood, N. W. , & Schapira, A. H. (2012). Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Annals of Neurology, 72, 455–463.
    1. McNeill, A. , Magalhaes, J. , Shen, C. , Chau, K. Y. , Hughes, D. , Mehta, A. , … Schapira, A. H. (2014). Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation‐linked Parkinson disease cells. Brain, 137, 1481–1495.
    1. Migdalska‐Richards, A. , Daly, L. , Bezard, E. , & Schapira, A. H. (2016). Ambroxol effects in glucocerebrosidase and a‐synuclein transgenic mice. Annals of Neurology , 80(5), 766–775.
    1. Migdalska‐Richards Schapira, A. H. (2016). The relationship between glucocerebrosidase mutations and Parkinson disease. Journal of Neurochemistry, 139, 77–90.
    1. Murphy, K. E. , & Halliday, G. M. (2014). Glucocerebrosidase deficits in sporadic Parkinson disease. Autophagy, 10(7), 1350–1351.
    1. Santini, E. , Sgambato‐Faure, V. , Li, Q. , Savasta, M. , Dovero, S. , Fisone, G. , & Bezard, E. (2010). Distinct changes in cAMP and extracellular signal‐regulated protein kinase signalling in L‐DOPA‐induced dyskinesia. PLoS One, 235(8), e12322.
    1. Schapira, A. H. , & Gegg, M. E. (2013). Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America, 110, 3214–3215.
    1. Sidransky, E. , Nalls, M. A. , Aasly, J. O. , Aharon‐Peretz, J. , Annesi, G. , Barbosa, E. R. , … Ziegler, S. G. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. The New England Journal of Medicine, 361, 1651–1661.
    1. Wang, Q. , Liu, Y. , & Zhou, J. (2015). Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Translational Neurodegeneration, 12, 4–19.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel